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ABSTRACT
Although a highly effective vaccine is available, the number of yellow fever cases has increased over the past 2 decades, which
highlights the pressing need for antiviral therapeutics. In a high-throughput screening campaign, we identified an acetic acid
benzodiazepine (BDAA) compound which potently inhibits yellow fever virus (YFV). Interestingly, while treatment of YFV-in-
fected cultures with 2MBDAA reduced the virion production by greater than 2 logs, the compound was not active against 21
other viruses from 14 different viral families. Selection and genetic analysis of drug-resistant viruses revealed that replacement
of the proline at amino acid 219 (P219) of the nonstructural protein 4B (NS4B) with serine, threonine, or alanine conferred YFV
with resistance to BDAAwithout apparent loss of replication fitness in cultured mammalian cells. However, replacement of P219
with glycine conferred BDAA resistance with significant loss of replication ability. Bioinformatics analysis predicts that the P219
amino acid is localized at the endoplasmic reticulum lumen side of the fifth putative transmembrane domain of NS4B, and the
mutationmay render the viral protein incapable of interacting with BDAA. Our studies thus revealed an important role and the
structural basis for the NS4B protein in supporting YFV replication. Moreover, in YFV-infected hamsters, oral administration of
BDAA protected 90% of the animals from death, significantly reduced viral load by greater than 2 logs, and attenuated virus in-
fection-induced liver injury and body weight loss. The encouraging preclinical results thus warrant further development of
BDAA or its derivatives as antiviral agents to treat yellow fever.
IMPORTANCE
Yellow fever is an acute viral hemorrhagic disease which threatens approximately 1 billion people living in tropical areas of Af-
rica and Latin America. Although a highly effective yellow fever vaccine has been available for more than 7 decades, the low vac-
cination rate fails to prevent outbreaks in at-risk regions. It has been estimated that up to 1.7 million YFV infections occur in
Africa each year, resulting in 29,000 to 60,000 deaths. Thus far, there is no specific antiviral treatment for yellow fever. To cope
with this medical challenge, we identified a benzodiazepine compound that selectively inhibits YFV by targeting the viral NS4B
protein. To our knowledge, this is the first report demonstrating in vivo safety and antiviral efficacy of a YFV NS4B inhibitor in
an animal model. We have thus reached a critical milestone toward the development of specific antiviral therapeutics for clinical
management of yellow fever.
Yellow fever is a mosquito-borne hemorrhagic disease that isfrequently associated with jaundice and is caused by yellow
fever virus (YFV) infection (1). Vaccination with attenuated YFV-
17D vaccine is the most important measurement to prevent yel-
low fever. The vaccine is safe, affordable, and highly effective, and
a single dose of the vaccine is sufficient to confer sustained immu-
nity and lifelong protection against yellow fever disease (2, 3).
However, the decline in herd immunity and discontinuation of
mosquito controlmeasures inmany parts of Africa are considered
the major causes for the resurgence of yellow fever and periodic
epidemics in East and West African countries during the last 2
decades (4). In addition, recent clinical studies also showed that an
activated immunemicroenvironment with other microbial infec-
tions prior to vaccination impeded efficacy of the YFV-17D
vaccine in an African cohort, suggesting that vaccine regimens
may need to be boosted in African populations to achieve effi-
cient protective immunity (5–7). It has been estimated that up
to 1.7 million YFV infections may occur in Africa each year,
resulting in 29,000 to 60,000 deaths (8, 9) (http://www.who
.int/csr/disease/yellowfev/yellowfeverburdenestimation
_summary2013.pdf). Once an outbreak starts, vaccination is less
effective, and other intervention strategies, such as antiviral ther-
apies, are needed. However, there are no specific antiviral thera-
peutics to treat the life-threatening disease, and development of
antiviral agents that inhibit YFV replicationwouldmeet a pressing
medical need (8).
YFV is the prototypic member of the Flavivirus genus in the
family Flaviviridae (10). The virus has a single-stranded, positive-
sense, approximately 11-kbRNAgenome. The viral genomicRNA
contains a single open reading frame that encodes a long polypro-
tein flanked by 5=- and 3=-untranslated regions (UTR) harboring
essential cis-elements for regulation of viral protein translation
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and RNA replication. The viral polyprotein is cotranslationally
and posttranslationally processed into three structural and seven
nonstructural (NS) proteins by host cellular and viral proteases.
While the three structural proteins, capsid (C), premembrane
(prM), and envelope (E), are involved in virion assembly and in-
fectious entry into host cells, the seven NS proteins, NS1, NS2A,
NS2B, NS3, NS4A, NS4B, and NS5, form membrane-bound rep-
lication complexes for replication of the viral RNA genome. Spe-
cifically, the three small hydrophobic proteins NS2A, NS4A, and
NS4B anchor the viral replication complex to the endoplasmic
reticulum (ER) membrane, and the NS5 protein functions as a
methyltransferase and RNA-dependent RNA polymerase to cata-
lyze viral RNA synthesis and facilitate viral RNA translation (11).
In addition to their distinct roles in viral replication, viral proteins
are also involved in activation and/or evasion of host innate and
adaptive immune responses and thus play important roles in
pathogenesis (12–14).
In the last decades, tremendous industrial and academic efforts
have been made in discovery and development of antiviral agents
against flaviviruses, most notably for dengue viruses (DENV) (15,
16). These efforts have resulted in identification of a variety of
small molecules that inhibit viral replication through targeting
distinct viral and host cellular functions (17–19). Small molecules
that specifically target viral capsid assembly (20), NS3/2A pro-
teases (21–23), NS3 RNA helicase (24), NS4B protein (25, 26),
NS5 methyltransferase (27), and RNA-dependent RNA polymer-
ase (28, 29) have been discovered, and the in vivo antiviral effica-
cies for four of these direct-acting antiviral (DAA) agents have
been demonstrated in animal models (24, 30–32); however, none
of them has reached human clinical trials. Balapiravir, a tri-isobu-
tyrate ester prodrug of 4=-azidocytidine (R1479) that was origi-
nally developed for treatment of chronic hepatitis C virus (HCV)
infection by Hoffmann-La Roche, is active against DENV in cul-
tured cells. However, a phase II clinical trial of Balapiravir for
treatment of dengue fever failed to improve the clinical and viro-
logical parameters in patients (33), most likely due to a DENV-
induced cytokine response that decreased the efficiency of conver-
sion of R1479 to its triphosphate form in mononuclear cells (34).
Compared to dengue virus and other flaviviruses, develop-
ment of antiviral agents against YFV has been less robust, perhaps
because of the availability of an effective vaccine and the difficulty
of conducting clinical trials during sporadic outbreaks of yellow
fever. Thus far, alpha interferon (IFN-) and a few broad-spec-
trum antiviral nucleoside analogues, including ribavirin, T-705,
and BCX4430, have been demonstrated to inhibit YFV replication
in vivo in hamsters (35–39). In addition, a high-throughput
screening effort using a subgenomic replicon cell-based pheno-
typic assay identified two small molecular compounds that inhib-
ited YFV, and their resistance mutation was mapped to the NS4B
gene (40). However, the antiviral efficacies of these compounds in
vivo in animal models have not been reported.
In a high-throughput screening with a HEK293 cell-based
IFN- promoter reporter assay, we identified a benzodiazepine
compound that potently inhibits YFV. Selection and genetic anal-
ysis of drug-resistant viruses revealed that replacement of the pro-
line at amino acid 219 of the NS4B protein with serine con-
ferred YFV resistance to the compound. Pharmacological studies
showed that the compound was well-tolerated in mice and ham-
sters, and oral administration of the compound protected 90% of
YFV-infected hamsters from death, significantly reduced the viral
load, and normalized liver function. The results thus strongly sup-
port the further development of the benzodiazepine compoundor
its derivatives as yellow fever therapeutics.
MATERIALS AND METHODS
Cell lines, virus stocks, and compounds. Huh7.5 (human hepatoma
cells; a gift of Charles M. Rice, Rockefeller University), HEK293 (human
embryonic kidney cells; ATCC), and Vero (green monkey kidney cells;
ATCC) cells were maintained in Dulbecco’s modified minimal essential
medium (DMEM; Invitrogen) supplemented with 10% fetal bovine se-
rum at 37°C (41). The C6/C36 mosquito cell line was purchased from
ATCC and maintained in Eagle’s minimum essential medium (EMEM)
supplemented with 10% fetal bovine serum at 28°C.
A plasmid containing the YFV 17D complete genomic cDNA,
pACNR/FLYF-17Dx, was a gift of CharlesM. Rice (42, 43). YFV 17D virus
stock was produced by electroporation of Huh7.5 cells with in vitro-tran-
scribed RNA from pACNR/FLYF-17Dx (44). The medium was harvested
at 48 h posttransfection, clarified by low-speed centrifugation, and stored
at80°C until use. The virus titers were determined by a plaque assay on
Vero cells as described previously (45).
BDAA and its enantiomers were synthesized in-house with greater
than 95% purity. Scale-up synthesis of BDAA for animal efficacy studies
was done by SRI International via the NIAID Preclinical Service Program.
Clinical psychoactive benzodiazepines (alprazolam, estazolam, nordiaz-
epam, temazepam, prazepam, and lorazepam) were obtained from a cer-
tified reference material provider (Cerilliant). Ribavirin was obtained
from ICN Pharmaceuticals, Inc. For in vivo studies, BDAA was prepared
in a solution of Solutol HS15 (Sigma-Aldrich) and methyl-2-pyrrolidi-
none (NMP; Sigma-Aldrich) in a 1:1 (wt/vol) ratio. Ribavirin was pre-
pared in sterile saline.
In-Cell Western assay. An In-Cell Western assay to simultaneously
detect YFV envelope protein and cell viability was performed essentially as
described previously (46). Briefly, Huh7.5 cells in a 96-well plate were
infected with YFV at a multiplicity of infection (MOI) of 0.1 and either
mock treated (1% dimethyl sulfoxide [DMSO]) or treated with a serial
dilution of BDAA for 48 h. Cells were fixed and incubated with a mouse
monoclonal antibody against flavivirus envelope proteins (4G2; Milli-
pore), followed by incubation with anti-mouse IRDye 800CW-labeled
secondary antibody together with two reagents for cell staining (DRAQ5
[Biostatus] and Sapphire700 [LI-COR]). YFV envelope protein expres-
sion and cell viability were visualized by using the LI-COR Odyssey sys-
tem.
qRT-PCR. Total cellular RNA was extracted from Huh7.5 or C6/C36
cells at 2 days postinfection (dpi) with YFV at the indicatedMOI by using
theNucleoSpin 96 RNAkit (Macherey-Nagel). The amounts of YFVRNA
were determined in a quantitative one-step reverse transcription-PCR
(qRT-PCR) assay by using a LightCycler 480II apparatus (Roche) and the
primers 5=-ATGCTGTCCCTTTTGGTTTG-3= and 5=-GCCACTGTGAG
TTTCAGCAA-3=. -Actin mRNA was quantified with the primers 5=-
CCAACCGCGAGAAGATGA-3= and 5=-CCAGAGGCGTACAGGGA
TAG-3= to normalize the levels of viral RNA inHuh7.5 cells.Aedes albopictus
S7 ribosomal mRNA was quantified with the primers 5=-GTCCACGATC
CCGCACTCT-3= and 5=-GTGGTCTGCTGGTTCTTGTCC-3= to nor-
malize the levels of viral RNA in C6/C36 cells.
Virus yield reduction assay. Monolayers of Vero or Huh7.5 cells in
24-well plates were infected for 1 h with serial 10-fold dilutions of the
culture medium harvested from YFV-infected cells with or without treat-
ment, followed by overlay with medium containing 0.75% methylcellu-
lose and incubation at 37°C for 3 to 5 days. Plaques were counted after
crystal violet staining (47).
Cytotoxicity assay. To determine the cytotoxicity of compounds, a
3-(4,5-dimethylthiazol)-2-(4-sulfophenyl)-2H-tetrazolium (MTT) assay
(Sigma) was performed. Uninfected Huh7.5 cells were mock treated or
treated with the indicated concentrations of testing compounds under
conditions that were identical to those used for the antiviral assays. The
Benzodiazepine Inhibitors Targeting YFV NS4B











dose-dependency curves were generated to determine the inhibitory con-
centration required to inhibit cell viability by 50% (CC50) by using Prism
5 (GraphPad Software, Inc.).
Selection and sequence analysis of resistant viruses. The YFV 17D
strain rescued from an infectious cDNA clone was used to infect Huh7.5
cells. Drug-resistant viruses were selected bymultiple rounds of passaging
of the viruses in cultures treated with increasing concentrations of BDAA.
Briefly, Huh7.5 cells grown in a 12-well plate were infected either with
wild-type YFV 17D at an MOI of 0.1 or in medium from a previous
passage that contained virus and the compound. After incubation at 37°C
for 1 h, the inocula were removed and replaced with fresh medium con-
taining BDAA. For each passage, the cell culture was incubated for 3 days,
during which time the cytopathic effect (CPE) was monitored as one of
the readouts for the development of resistance. The viruses were passaged
6 times in the presence of 3MBDAA, followed by passage 6 times in the
presence of 6MBDAA and 6 times in the presence of 8MBDAA. As a
control, wild-type YFV 17D was passaged in the presence of 0.5% DMSO
in parallel. The viruses in the supernatants of the 12th passage in the
presence of 6MBDAA and 18th passage in the presence of 8MBDAA
were evaluated for compound sensitivity in a yield reduction assay. To
map drug resistance mutations, virus in the 18th passage was used to
infect Huh7.5 cells. Total cellular RNAs were extracted on day 3 postin-
fection. YFV cDNA was synthesized and amplified by RT-PCR. Purified
PCR products were used for direct DNA sequencing (Genewiz). Muta-
tions were identified by sequence alignment with parental YFV 17D
cDNA.
Recombinant virus cDNA construction. To construct full-length
YFV 17D cDNA clones containing the desired NS4B P219 mutations,
995-bp fragments flanking theNS4B P219 site with the desired nucleotide
substitutions to confer P219S, P219T, P219A, or P219G mutations were
synthesized and confirmed by DNA sequencing (GenScript). The corre-
sponding fragment in pACNR/FLYF-17Dx was then replaced with the
synthesized fragments to yield plasmids containing full-length YFV 17D
cDNA clones with the desired point mutations. Mutant viruses were res-
cued by electroporation of Huh7.5 cells with in vitro-transcribed RNA
from each of the recombinant YFV cDNA clones. The medium and cells
were harvested at 4 to 6 days posttransfection. Virus titers were deter-
mined by a plaque assay in Vero or Huh7.5 cells.
Benzodiazepine receptor binding assay. The binding activities of
BDAA to benzodiazepine receptors were assessed in a radioactive-labeled
ligand competition binding assay (48, 49). The central nervous system
benzodiazepine receptor (GABAAR) was prepared from rat cerebral cor-
tex, and the peripheral nervous system benzodiazepine receptor (PBR)
was prepared from rat heart. [3H]flunitrazepam and [3H]PK11195 were
used as the labeled agonists, and diazepam and unlabeled PK11195 were
used as reference agonists for the central nervous system and peripheral
nervous system benzodiazepine receptor binding assays, respectively. The
bound and unbound labeled ligands were separated by centrifugation,
and bound labeled ligands were quantified by scintillation counting.
Pharmacokinetics of BDAA. Single-dose pharmacokinetics (PK)
studies were performed for BDAA in mice. Intravenous (i.v.), oral (per os
[p.o.]), intramuscular (i.m.), or intraperitoneal (i.p.) administration
routes were included with dose levels of either 2 mg/kg of body weight
(i.v.) or 10 mg/kg for all other routes (IAS, Berkeley, CA). Following each
administration, at various time points postadministration blood samples
were collected to determine the plasma concentration of the test com-
pound. Three female CD-1 mice per time point were used. The single-
compartment PK parameters were calculated using PK functions within
Excel.
In vivo toxicity analysis in mice and hamsters. A repeated-dose oral
study and i.p. maximum tolerated dose (MTD) study (MB Research Lab-
oratories, Spinnerstown, PA) for BDAA were performed in CD-1 mice at
5, 10, 25, 50, and 100 mg/kg every 8 h for 7 days. Each treatment group
included three mice. The animals were observed once daily for mortality
and body weight changes as well as any sign of illness.
A repeated-dose oral MTD study for BDAA was performed in female
Syrian golden hamsters at 50, 100, and 150 mg/kg twice daily for 7 days.
Each treatment group included 5 animals. The animals were observed
once daily for mortality and body weight changes as well as any sign of
illness.
Antiviral efficacy in YFV-infected hamsters. The in vivo efficacy ex-
periments were performed using lethal YFV infection of hamsters as re-
ported previously (36, 37). Female Syrian golden hamsters (Charles River
Laboratories) with an average weight of 110 gwere used after a quarantine
period of greater than 48 h. Randomly grouped animals were infected
with Jimenez, a hamster-adapted YFV strain, via i.p. inoculation, at 10
50% tissue culture infective doses (TCID50)/animal. The infected ham-
sters (n  10 per group) were treated twice daily with 100 mg/kg, 50
mg/kg, or 25mg/kg of BDAA for 7 days beginning at 4 h prior to infection
via oral administration. Ribavirin was included as a positive control and
was administered orally at 25 mg/kg with the same treatment schedule. A
placebo-treated infection control group was included, and these animals
were treated with the same vehicle used for BDAA. Sham-infected con-
trols (n 5 per group) were either treated with the highest dose of BDAA
using the same schedule and route of administration to monitor for signs
of toxicity, and negative controls were treated with vehicle. Uninfected
and untreated normal controls (n 5) were also included as controls for
weight changes andmortality. The survival rate was observed until day 21
postinfection. Bodyweights weremeasured on 3 and 6 days postinfection.
Serum was collected via ocular sinus bleed on 4 and 6 days postinfection.
An alanine aminotransferase (ALT) assaywas performedwith serum sam-
ples obtained 6 days postinfection and added into a commercial reagent
(TecoDiagonostic, Anaheim, CA). The virus titers were determined using
serum samples from 4 days postinfection in a CPE-based infectious cell
culture assay in Vero 76 cells to calculate the endpoint of infection (35).
Ethics statement. The in vivo efficacy study, including veterinary care
and experimental procedures, was reviewed and approved by the Institu-
tional Animal Care and Use Committee of Utah State University (identi-
fication number 2400). The study was carried out in accordance with the
recommendations and guidelines of the National Institutes of Health for
the care and use of laboratory animals.
Statistical analyses. In the in vivo efficacy study, survival data were
analyzed using the Wilcoxon log-rank survival analysis, and all other sta-
tistical analyses were performed using a one-way analysis of variance
(ANOVA)with a Bonferroni group comparison (Prism5;GraphPad Soft-
ware, Inc.).
RESULTS
Discovery of a benzodiazepine compound that specifically in-
hibits YFV. We reported previously that infection of a HEK293
cell-based reporter cell line expressing firefly luciferase under the
control of a human IFN- promoter with several RNA viruses,
includingDENVandYFV, activated reporter gene expression that
correlated quantitatively with the levels of virus replication and
progeny virus production. This assay had been used for high-
throughput screening of compounds that inhibited either viral
replication or the virus-induced proinflammatory cytokine re-
sponse (45). Through screening of an in-house small-molecule
library, we identified a benzodiazepine compound, 2-(S)-3-[(S)-
sec-butyl]-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e]
(1,4)diazepin-1-ylacetic acid, designated BDAA (Fig. 1A), that in-
hibited DENV serotype 2 (DENV-2) and YFV infection. Its anti-
viral activity against YFV was demonstrated in three independent
assays in humanhepatoma cell lineHuh7.5. As shown in Fig. 1B to
D, BDAAcaused dose-dependent inhibition of YFV envelope pro-
tein expression, RNA replication, and progeny virion production,
as demonstrated in In-CellWestern, qRT-PCR, and plaque assays,
respectively. The 50% effective concentrations (EC50s) of the
compound in the three assays were between 0.21 and 0.9 M.
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Moreover, treatment of YFV-infected cultures with 2 or 10 M
BDAA reduced progeny virion production by2 to 4 logs. Cyto-
toxicity of the compounds was determined in an MTT assay in
Huh7.5 cells, and CC50 values were greater than 100 M. In addi-
tion toHuh7.5 cells, similar antiviral results against YFVwere also
obtained in HEK293 and Vero cells in a qRT-PCR assay (Table 1).
Investigation of the antiviral spectrum through the National In-
stitutes of Health (NIH) in vitro antiviral screening program
showed that BDAA is a potent YFV inhibitor which inhibited
YFV-induced CPE, with an EC50 of 0.05 M, and reduced YFV
yields, with an EC90 of 0.03 M in Vero cells. In addition, BDAA
also modestly reduced DENV-2 yield, with an EC90 of 8.6 M.
However, the compound did not apparently inhibit the infection/
replication of 21 other viruses from 14 different virus families,
including four additional representative human-pathogenic flavi-
viruses (Table 1). The narrow antiviral spectrum suggests that
BDAA most likely targets a YFV-specific function.
Antiviral activity of BDAA enantiomers against YFV. BDAA
is a benzodiazepine compound with two chiral centers. We there-
fore synthesized and compared the antiviral activity of the four
enantiomers against YFV (Fig. 2A). As shown in Fig. 2B, the rank
order of the potency of the enantiomers to inhibit YFV RNA rep-
lication in Huh7.5 cells was (S,S)  (S,R)  (R,S)  (R,R), with
EC50s of 0.2, 0.5, 2.4, and10 M, respectively. We note that the
BDAA compound in our chemical library is an (S,S) enantiomer.
These results suggest a critical role of the S chiral configuration at
the alpha carbon atom in inhibition of YFV replication and estab-
lish a basis for further lead optimization efforts toward identifica-
tion of benzodiazepine derivatives with superior pharmacological
properties and antiviral activities against YFV.
Antiviral and benzodiazepine receptor binding activities de-
pend on distinct structural features. Benzodiazepines are the
most common antianxiety drugs administered around the world
(50). This class of drugs works by allosterically modulating the
binding of the neurotransmitter gamma-aminobutyric acid
(GABA) to the GABAA receptor (GABAAR), an ionotropic recep-
tor and ligand-gated ion channel, which results in sedative, hyp-
notic (sleep-inducing), anxiolytic (antianxiety), anticonvulsant,
muscle relaxant, and other pharmacological properties (51). Ben-
zodiazepine drugs can also interact with peripheral benzodiaz-
epine receptors (PBR), which are structurally unrelated to
GABAAR and are present in the peripheral nervous system and
other tissues. Binding of benzodiazepines to PBRs modulates im-
mune responses and other host functions (52).
Benzodiazepine is a chemical name for compounds with a core
structure of fused benzene and diazepine rings. Benzodiazepine
drugs are substituted 1,4-benzodiazepines with different side
groups attached to this core structure. The different side groups
affect the binding of the molecule to GABAAR and thus modulate
the pharmacological properties. Interestingly, BDAA is structur-
ally similar to benzodiazepine drugs used in the clinic. Therefore,
it is very important to know whether BDAA binds GABAAR
and/or peripheral benzodiazepine receptors. Obviously, our goal
is to develop benzodiazepines with potent anti-YFV activity, but
without psychiatric or other pharmacological/toxicological activ-
ities. Accordingly, the goals of our lead optimization efforts are
not only to improve the antiviral activity, but also, more impor-
tantly, to focus on identifying lead compounds with favorable
pharmacological properties and without GABAAR and/or PBR
binding activities.
To investigate the structure-activity relationship (SAR) of ben-
zodiazepines in antiviral and receptor binding activities, we first
tested six representative clinical psychoactive benzodiazepine
drugs (Fig. 3A) for their antiviral activities against YFV. As shown
in Fig. 3B, while BDAApotently inhibited YFVRNA replication in
Huh7.5 cells, none of the six clinically used benzodiazepine drugs
demonstrated any detectable inhibitory effects on YFV infection.
FIG 1 In vitro antiviral activity of BDAA against YFV. (A) Structure of BDAA.
(B) Huh7.5 cells seeded in 96-well plates were infected with YFV strain 17D at
anMOI of 0.1 for 1 h, followed by treatment with the indicated concentrations
of BDAA for 48 h. YFV E protein was visualized by In-Cell immunostaining
(green). Cell viability was determined using DRAQ 5 and Sapphire 700 stains
(red). (C and D) Huh7.5 cells seeded in 96-well plates were infected with YFV
at an MOI of 0.01 for 1 h, followed by treatment with the indicated concen-
trations of BDAA for 48 h. Total intracellular RNAs were extracted to deter-
mine the amount of YFV RNA by qRT-PCR. YFV RNAs were normalized to
-actin mRNA and presented as the percentage of mock treated control (C).
Data represented the mean results from four independent replicates ( stan-
dard deviations). Culture media were harvested from infected cells treated
with various concentrations of BDAA to determine the virus titer in a plaque
assay in Vero cells (D). Values represent average results from a triplicate ex-
periment ( standard deviations). EC50, EC90, and CC50 values were calcu-
lated using Prism 5 (GraphPad Software, Inc.).
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Next, we tested if BDAA competitively inhibited the binding of
[3H]flunitrazepam and [3H]PK11195, representative benzodiaz-
epine drugs, to their cognate receptors, GABAAR andPBR, respec-
tively. In this assay, an inhibition of more than 50% of the labeled
ligand binding by a test compound indicates a strong benzodiaz-
epine receptor binding activity. On the contrary, an inhibition of
less than 20% of the labeled ligand binding is interpreted as no
specific binding activity of the test compound. As shown in Fig.
3C, while 0.3 M diazepam and PK11195 completely inhibited
the labeled ligands binding to GABAAR and PBR, respectively, 10
M BDAA reduced the labeled ligand binding to their cognate
receptors by less than 15%. The results thus indicate that the anti-
YFV and psychiatric activities of benzodiazepines rely on distinct
structural features, and development of benzodiazepine anti-YFV
drugs without psychiatric activities is possible.
BDAA does not inhibit the early steps of YFV replication.As
the first step toward understanding the antiviral mechanism of
BDAA, we performed a time-of-addition experiment to map the
viral replication step(s) inhibited by the compound during a syn-
chronized YFV infection of Huh7.5 cells. As shown in Fig. 4A,
pretreatment as well as treatment of Huh7.5 cells during the virus
inoculation period did not inhibit YFV infection, as indicated by a
normal onset of viral RNA replication in the infected cultures.
Those results imply that the compound neither inactivates the
infectivity of YFV nor inhibits the infectious entry of YFV. Inter-
estingly, addition of BDAA as late as 12 h postinfection was still
able to potently inhibit viral RNA replication, and treatment start-
ing at 24 h postinhibition reduced viral RNA by approximately
40%. A similar result was obtained in a parallel study that mea-
sured the YFV titers in the culture medium (Fig. 4B). These ob-
servations indicated that BDAA most likely inhibits a postentry
step of YFV replication.
Selection and genetic analysis of BDAA-resistant YFV. In or-
der to determine the viral target of BDAA, we selected drug-resis-
tant YFV strains via a procedure depicted in Fig. 5A. Briefly,
Huh7.5 cells were infected by YFV 17D and cultured in the pres-
ence of the indicated concentrations of BDAA. After 3 days, cul-
ture medium was harvested and inoculated into a fresh Huh7.5
culture in the presence of BDAA. Extensive CPE was observed at
passage 18 in cells treated with 8 M BDAA, suggesting the out-
growth of BDAA-resistant YFV. Resistance of the selected YFV
strain to BDAA was validated in Huh7.5 cells with a virus yield
reduction assay. As shown in Fig. 5B, BDAA reduced the yield of
parental YFV 17D, with an EC50 of 0.1 M, but reduced the yield
of BDAA-selected YFV, with an EC50 of 3.2 M. More strikingly,
the EC90s of BDAA to reduce the yields of wild-type (WT) YFV
17D and BDAA-selected YFV were 0.9 and 28.5 M, respectively,
suggesting successful selection of highly BDAA-resistant YFV.
In order to map the BDAA resistance mutations, six over-
lapped cDNA segments covering the entire genomic RNA of the
drug-resistant YFV as well as parental YFV 17Dwere amplified by
RT-PCR. The PCR products were subjected for direct DNA se-
quencing. Sequence alignments between the parental and drug-
resistant viruses revealed only a single-nucleotide mutation, from
TABLE 1 Antiviral spectrum of BDAAa
Virus Family Strain Cell type Assay EC50 EC90 CC50
Herpes simplex virus 1 Herpesviridae E-377 HFF CPE 100 ND 100
Human cytomegalovirus AD169 HFF CPE 100 ND 100
Rift Valley fever virus Bunyaviridae MP-12 Vero 76 CPE 18 ND 43
Tacaribe virus Arenaviridae TRVL11573 Vero CPE 18 ND 40
Venezuelan equine encephalitis virus Togaviridae TC-83 Vero CPE 32 ND 32
BK virus Papovaviridae Gardner HFF CPE 62.4 ND 100
JC virus MAD-1 Cos7 qPCR 95.5 ND 100
Vaccinia virus Poxviridae Copenhagen HFF CPE 100 ND 100
SARSb coronavirus Coronaviridae Toronto-2 Vero E6 CPE 100 ND 100
Influenza A H1N1 virus Othomyxoviridae Influenza A/California/7/2009 MDCK CPE 100 ND 100
Hepatitis B virus Hepadnaviridae ayw HepG2.215 Hybridization 100 ND 100
Respiratory syncytial virus Paramyxoviridae A Hep-2 CPE 100 ND 100
Human papillomavirus Papillomaviridae HPV-11 HEK293 qPCR 3 71 100
Norovirus Caliciviridae GI HG23 Hybridization 100 ND 100
Encephalomyocarditis virus Picornaviridae Huh7.5 Yield reduction 10 ND 100
Hepatitis C virus Flaviviridae Con-1 Huh-luc/NeoET Luciferase reporter 20 ND 20
HCVcc JC1 Huh7.5 qPCR 10 ND 100
Bovine viral diarrhea virus NADL MDBK Yield reduction 10 ND 100
West Nile virus KERN515 WN02 Vero 76 CPE 32 ND 32
Japanese encephalitis virus SA-14 Vero 76 CPE 57 ND 57
Powassen virus LB BHK-21 CPE 32 ND 32
Zika virus Zika-016 Vero 76 CPE 100 ND 100
Dengue virus DENV-2 New guinea C Vero Yield reduction ND 8.6 50
Yellow fever virus 17D Vero 76 CPE 0.05 ND 50
Vero 76 Yield reduction ND 0.03 50
Huh7.5 qPCR# 0.21 0.37 100
HEK293 qPCR# 0.17 0.30 50
Vero qPCR# 0.13 0.27 100
a All the assays were performed by the NIAID Pre-clinical Service Program, except for those marked with a #, which were conducted in-house at Baruch S. Blumberg Institute. The
EC50, EC90, and CC50 values reported are the micromolar concentrations. ND, not determined.
b SARS, severe acute respiratory syndrome.
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C toU, at nucleotide 7423 in BDAA-resistant YFV, which resulted
in the replacement of proline at amino acid 219 (P219) of the
NS4Bproteinwith a serine (Fig. 5C). Sequence alignment ofNS4B
indicated that P219 is absolutely conserved in all the 38 full-length
YFV sequences deposited in GenBank, but it is replaced with a
threonine at the position in DENV, West Nile virus (WNV), and
Japanese Encephalitis virus (JEV) or with a serine in Zika virus
(ZIKV). Such a differencemay account for the selective inhibition
of BDAA for YFV but not other flaviviruses.
The flaviviral NS4B are integral membrane proteins and are
primarily localized in cytoplasmic foci originating from the endo-
plasmic reticulum (ER) (53). Studies of DENVNS4B suggest that
the protein is an essential component of the viral RNA replication
complex (54). It has also been demonstrated that theDENVNS4B
protein antagonizes the virus-induced type I interferon response
andmay thus play a role in viral pathogenesis (55). Bioinformatics
analysis predicts that the YFVNS4B protein contains five putative
intra- or transmembrane domains (pTMD1 to pTMD5), with a
membrane topology in which the N-terminal part resides in the
ER lumen, while the C-terminal part is composed of three trans-
membrane domains with the C-terminal tail localized in the cyto-
plasm. This model is generally consistent with experimentally de-
termined topology of the DENV NS4B protein (53). P219 resides
at the N terminus of the fifth putative transmembrane domain,
pTMD5 (Fig. 5C).
Effects of P219 substitutions on YFV replication and resis-
tance. To confirm that P219S mutation does confer BDAA resis-
tance and to investigate the role of P219 in NS4B function and
BDAA inhibition of YFV replication, we produced YFV 17D vi-
ruses with a P219S, P219T, P219A, or P219G mutation by engi-
neering the desired mutations in the infectious YFV 17D cDNA
clone and rescuing the mutant viruses by transfection of in vitro-
transcribed RNA into Huh7.5 cells. While parental YFV 17D,
P219S, or P219T RNA induced CPE at day 4 posttransfection,
P219G and P219A RNA caused CPE at day 5 and 6 posttransfec-
tion, respectively. At the day of CPE appearance, culture media
were harvested. The cells were lysed in serum-freeDMEMby three
freeze-thaw cycles. The cell lysates were cleared by centrifugation
at 1,000	 g and 4°C for 10 min. The virus titers in culture media
were determined in Vero cells via a plaque assay.While the paren-
tal YFV 17D, P219S, P219T, and P219A RNA-transfected cells
produced similar amounts of viruses, ranging from 8 	 104 to
1.2	 105 PFU/ml, and caused similar sizes of plaques in Vero cell
monolayers, no infectious virus could be detected from the cul-
FIG 2 Antiviral activity of BDAA enantiomers. (A) Structures of BDAA and its enantiomers. (B) Determination of the antiviral activities of BDAA and its
enantiomers from a qRT-PCR assay. Huh7.5 cells were cultured and treated as described for Fig. 1C. YFVRNAswere normalized to-actinmRNA levels and are
presented as percentages of mock-treated control results. Values represent the mean results from four independent replicates ( standard deviations). EC50 and
EC90 values were calculated using Prism 5 (GraphPad Software, Inc.).
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turemedium of P219GRNA-transfected cells.We then compared
the yields of cell-free (medium) and cell-associated (lysate) viruses
between YFV 17D and P219G RNA-transfected cells in a plaque
assay inHuh7.5 cell monolayers.We found that while the yields of
cell-associated viruses were similar between YFV 17D and P219G
RNA-transfected cells, P219G RNA-transfected cells produced
approximately 60-fold less cell-free viruses than did YFV 17D
RNA-transfected cells. Moreover, P219G virus produced smaller
plaques. These results indicated that the NS4B P219G mutation
may compromise virus replication and/or secretion of infectious
virions.
To investigate the biological properties of the mutant viruses,
we first examined the cell-free viruses rescued from Huh7.5 cells
transfectedwith parental YFV17D, P219S, P219T, or P219ARNA.
Infection of the three mutant viruses caused an accumulation of
viral RNA and produced infectious virions with similar kinetics in
Huh7.5 cells as did parental YFV 17D (Fig. 6A and B). We next
determined the sensitivity of the three mutant viruses to BDAA.
As shown in Fig. 6C andD, while BDAA efficiently inhibited wild-
type YFV 17D RNA replication and reduced viral yields, all three
mutant viruses were resistant to BDAA, and the P219S mutant
virus demonstrated the highest level of resistance to BDAA inhi-
bition of viral RNA replication and infectious virion production.
In order to determine the effects of the P219G substitution on
viral replication and virion secretion,we first infectedHuh7.5 cells
with cell-associated viruses harvested from YFV 17D and P219G
RNA-transfected Huh7.5 cells to compare the kinetics of viral
RNA replication (Fig. 7A) and production of cell-associated (Fig.
7B) and secreted (Fig. 7C) viruses. The results clearly demon-
strated that the P219G mutant YFV has approximately 10-fold
lower viral RNA replication as well as production of both cell-
associated and cell-free viruses, suggesting that themutation com-
FIG 3 The anti-YFV and psychiatric activities of benzodiazepines require distinct structural features. (A) Structures of six representative clinically psychoactive
benzodiazepines. (B) Determination of the antiviral activities of clinically used benzodiazepines based on a qRT-PCR assay. Huh7.5 cells were cultured and
treated as described for Fig. 1C. YFVRNA levels were normalized to-actinmRNA levels and are presented as the percentage of themock-treated control values.
Values represent themean results from four independent replicates ( standard deviations). (C) The affinities of BDAA to central and peripheral nervous system
benzodiazepine receptors were measured in radioligand competitive binding assays. The binding of [3H]flunitrazepam and [3H]PK11195 to the corresponding
benzodiazepine receptors was measured in the presence or absence of 10 M BDAA, and the effects of BDAA on radioligand banding are expressed as the
percentage of themock-treatment control. The reference compounds diazepamandnonlabeled PK11195with knownbenzodiazepine receptor binding activities
were tested at 0.3 M. Values represent the mean results from duplicate experiments ( standard deviations).
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promises viral RNA replication but does not directly affect virion
assembly and secretion. Moreover, despite lower replication and
progeny virion production, the P219G virus is highly resistant to
BDAA in Huh7.5 cells (Fig. 7D and E).
The antiviral effect of BDAAagainst wild-type 17D andmutant
recombinant YFV was further tested in the mosquito cell line C6/
C36. Figure 8 shows that the resistance profile in C6/C36 cells was
similar to that in Huh7.5 cells. While BDAA efficiently inhibited
wild-type YFV 17D RNA replication, with an EC50 of 0.08M, all
three mutant viruses were resistant to BDAA, with EC50s ranging
from 0.4 to 4.7 M, among which the P219S mutant virus dem-
onstrated the highest level of resistance to BDAA inhibition.
Taken together, our results imply that while proline 219 is crit-
ical to confer sensitivity to BDAA, it is not essential for YFV rep-
lication, because it can be replaced with amino acids containing a
small nonpolar hydrophobic side chain (A) or polar uncharged
side chain (S or T) without apparent loss of replication fitness in
both human and mosquito cells. Mechanistically, the similar re-
sistant profiles of NS4Bmutants in both the human andmosquito
cells imply that the amino acid P219 residues may mediate the
direct binding of BDAA to the YFV NS4B protein. Nevertheless,
the high conservation of P219 in all the clinical/field YFV isolates
suggests that P219 is important for viral replication fitness in hu-
man and mosquitoes and thus favors the development of BDAA
or its derivatives as antiviral agents for the treatment of yellow
fever.
Evaluation of pharmacological and toxicological properties
of BDAA. In order to determine the dosing schedule and route of
administration for the in vivo antiviral efficacy study in animals,
we first determined the pharmacokinetics of BDAA in mice. A
single dose of BDAA was administered i.v., p.o., s.c., i.m., or i.p.
routes, and blood samples were obtained at various time points
postadministration to determine the plasma drug concentrations.
The pharmacokinetic studies of BDAA indicated that BDAAdem-
onstrated good oral bioavailability (35%) and good retention of
drug. For instance, at 8 h post-oral administration of 10 mg/kg
BDAA, the plasma concentration of BDAAwas maintained above
0.2 M. Assuming a linear relationship was maintained with in-
creased dosages, at a dose of 50mg/kg, BDAAcould bemaintained
in the plasma at the level that is above the EC90 for inhibition of
YFV in culture, for at least 8 h post-single oral dosing (data not
shown).
In order to find theMTD of BDAA in animals, a repeated-dose
oral and i.p. MTD study was performed in mice. The results
showed that oral administration of BDAA at the highest dose
tested (100 mg/kg three times daily for 7 days) was very well tol-
erated. However, administration of BDAAwith a dosing schedule
of 100 mg/kg three times daily via the i.p. route caused significant
toxicity to all the animals, which were euthanized on day 4 or 5. A
repeated-dose oral MTD study was also performed in hamsters
and showed that BDAA was well tolerated at the highest dose
tested (150 mg/kg twice daily for 7 days).
Antiviral efficacy of BDAA in YFV-infected hamsters. The
above in vivo toxicology studies showed that BDAA is better tol-
erated with oral administration. The highest equilibrium solubil-
ity of BDAA in solutol:cremaphore:saline diluent was 100 mg/ml.
Due to its relatively low aqueous solubility, it was difficult to keep
BDAA in solution in order to dose the animals at the 150-mg/kg
dose. Hence, a 100-mg/kg/dose level was selected as the highest
dose for the efficacy study. Grouping and treatment schedules for
YFV-infected hamsters are described in the legend of Fig. 9. The
infected animal survival rate, body weight changes between 3 to 6
dpi, levels of serum ALT at 6 dpi, and also virus titers at 4 dpi in
serum were measured to determine the activities of the test com-
pound in suppressing viral replication and improving viral disease
management.
As shown in Fig. 9A, improvement of YFV-infected animal
survival was observed in groups treated with 100 mg/kg or 50
mg/kg of BDAA twice daily orally, although this was only statisti-
cally significant (P 
 0.05 [compared with the placebo control
group]) for the group treated with 50 mg/kg of BDAA. This was
likely due to the relatively higher survival rate in the placebo-
treated group. Both of these two dosing groups performed slightly
better than the ribavirin-treated controls (70% survival). The low-
est dose of 25mg/kg BDAA twice daily resulted in a survival curve
that was similar to that for placebo treatment.
Comparing the weight changes between 3 and 6 dpi among the
treatment groups, significant improvements in animals treated
FIG 4 Time-of-addition analysis of BDAA antiviral activity against YFV.Huh7.5 cells were infected with YFV at anMOI of 10 for 1 h. BDAA (5M)was present
either transiently for 2 h before infection (2 to 0), during infection (0, 1), or added at the indicated time points until 48 h postinfection. For each time point,
1% DMSO was added to mock-treated controls. Total intracellular RNAs were extracted, and culture media samples were collected at 48 h postinfection to
determine the amounts of YFVRNA in a qRT-PCR assay (A) and virus titers were determinedin a plaque assay (B). YFVRNAswere normalized to-actinmRNA
levels. The graph denotes the percentages of YFVRNA relative to that of themock-treated control added at the time of infection (time point 0). Virus titers in the
culture media were measured by plaque assay in Vero cells. Each data point is the mean results from four independent replicates ( standard deviation).
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with either 100 or 50 mg/kg (P
 0.01 and P
 0.05, respectively)
were observed. However, treatment with 25 mg/kg of BDAA re-
sulted in a weight change curve similar to that for the placebo
control group. The weight change curve of animals treated with
ribavirin was similar to that of normal control animals and was
significantly improved compared with placebo (P 
 0.001)
(Fig. 9B).
Serum levels of ALT, a biomarker for hepatocyte injury, at 6
dpi were significantly reduced in animals treated with 100 mg/kg
of BDAA (P 
 0.01). A trend toward reduced ALT was also ob-
served in the 50-mg/kg/dose group, although this reduction was
not significant. As with survival and weight change, serum ALT
levels in animals treated with 25 mg/kg of BDAA were similar to
those in placebo-treated animals, further confirming the inactivity
FIG 5 Selection and characterization of BDAA-resistant YFV. (A) Schematic representation of the procedure to select BDAA-resistant YFV. At the 18th passage,
CPE was observed in the culture treated with BDAA. The culture medium was harvested as a BDAA-resistant YFV stock. (B) Effects of BDAA on parental YFV
17D and BDAA-resistant virus were determined in a virus yield reduction assay. Values represent average results from two independent wells with duplication
for virus titer titration. EC50 and EC90 values were calculated using Prism 5 (GraphPad Software, Inc.). (C) Alignment of the amino acid sequence flanking the
putative NS4B protein transmembrane domain 5 (pTMD5) of YFV and other flaviviruses. The predicted membrane topology of YFV NS4B is shown at the top
of amino acid sequence. Amino acid P219 of YFV is highlighted.GenBank accession numbers for the listed viruses are as follows: YFV strain 17D (X03700.1), YFV
strain BeH655417 (JF912190.1), DENV-1Western Pacific strain (U88536.1), DENV-2 New Guinea C strain (AF038403.1), DENV-3 H87 strain (KU050695.1),
DENV-4 rDEN4 clone (AF326825.1), WNVNY99 (NC_009942.1), JEV JaOArS982 strain (M18370.1), and ZIKV strain BeH819966 (KU365779.1). The amino
acid position of NS4B is numbered according to that for YFV 17D.
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of the compound at this dose. Ribavirin treatment also signifi-
cantly reduced serum ALT, as expected (P
 0.001) (Fig. 9C).
Finally, dosing with 100 mg/kg of BDAA beginning just prior
to virus challenge resulted in an approximate 2-log10 reduction in
average virus titer in serum at 4 dpi compared with placebo treat-
ment, which was statistically significant (P
 0.001). A reduction
in virus titer was also observed in animals treatedwith 50mg/kg of
BDAA (P 
 0.05) or in those treated with ribavirin (P 
 0.01)
(Fig. 9D).
In the efficacy studies, sham-infected animals were also in-
cluded as controls. In sham-infected animals, treatment with 100
mg/kg BDAA twice daily for 7 days did not produce any signs of
toxicity, as judged by weight changes and ALT levels, compared
with placebo-treated animals and normal animals without sham
infection or treatment.
DISCUSSION
We report herein the discovery of a benzodiazepine compound,
BDAA, that potently inhibits YFV replication by specifically tar-
geting NS4B protein. Because benzodiazepines are well-known as
antianxiety drugs that bind GABAA receptor and PBRs, intensive
attention has been paid to the potential neurologic and psychiatric
activities of BDAA in our studies. Fortunately, we obtained several
lines of evidence suggesting that the anti-YFV and psychiatric ac-
tivities of benzodiazepines rely on distinct structural features. Spe-
cifically, while all six psychoactive benzodiazepine drugs do not
inhibit YFV replication, BDAA had negligible GABAAR and PBR
binding activities (Fig. 3). Furthermore, in our repeated-dose
maximum tolerated dose studies, central nervous system effects,
including tremors and convulsions, changes in the level of activity,
gait, and posture, reactivity to handling or sensory stimuli, altered
strength, and stereotypic or bizarre behavior (e.g., self-mutilation,
walking backwards), were not observed in all the BDAA-treated
mice. In addition, compounds with the benzodiazepine scaffold
have been reported to have antiviral activities against respiratory
syncytial virus (56), hepatitis B virus (57), filoviruses (58), and
human immunodeficiency virus (59). Hence, development of
benzodiazepine derivatives with potent anti-YFV activity, but
without psychiatric side effects, is plausible.
Concerning the antiviral mechanism of BDAA, a single amino
acid substitution in NS4B, P219S, was identified to confer YFV
resistance to BDAA. NS4B is a nonenzymatic integral membrane
protein (53). Flaviviral NS4B proteins participate in viral RNA
replication and evasion of host innate immune response (55). The
critical roles of this protein in viral replication and pathogenesis
are well illustrated by the fact that many cell culture and animal
adaptive mutations map to NS4B (60). Although the exact func-
tional involvement of flavivirus NS4B in the viral replication cycle
and the molecular mechanism to evade host innate immunity re-
main to be determined, prior studies have already demonstrated
FIG 6 Antiviral activity of BDAA against replication-competent recombinant YFV with P219 mutations in Huh7.5 cells. (A and B) Replication kinetics of
recombinant viruses with different P219mutations.Huh7.5 cells were infected at anMOI of 0.1 for 1 h. Total cellular RNAswere extracted, and the culturemedia
were collected fromcells at the indicated time points postinfection. YFVRNAwas detected by a qRT-PCR assay andnormalized to-actinmRNA levels. TheYFV
RNAarbitrary units are the amount relative to that of the RNA level in uninfected cells (A). Supernatants from the cultureswere used to determine the virus yields
in a plaque assay (right panel). Data presented aremean results from two independent replicates with duplication in the plaque assay ( standard deviations) (B).
(C and D) Sensitivity of recombinant viruses to BDAA. Huh7.5 cells were infected with YFV 17D or mutant virus at an MOI of 0.1 and mock treated or treated
with indicated concentrations of BDAA for 48 h. Total cellular RNAs were extracted to detect YFVRNA in a qRT-PCR assay, using-actin as an internal control.
Values are the percentage relative to mock-treated controls (C). Supernatants from the cultures were harvested to determine the virus yields in a plaque assay in
Vero cells (D). Data are mean results from four independent replicate experiments ( standard deviation).
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thatNS4B dimerization and interactionwith other viral nonstruc-
tural proteins, including NS1, NS2A, NS3, and NS4A, as well as
many host cellular proteins, are important for its function in viral
RNA replication and antagonism of the immune response (14, 31,
61, 62). It is thus conceivable that blocking the NS4B protein in-
teraction with other viral and host cellular proteins could lead to
direct inhibition of viral RNA replication or, alternatively, could
act through activation of the host innate antiviral response to re-
strict viral replication.
Interestingly, several structurally distinct compounds have
been identified that inhibit DENV or YFV replication through
targetingNS4B (40, 63–67). In addition,multiple inhibitors of the
NS4B protein of hepatitis C virus, a distantly related member of
the Flaviviridae family, are currently under preclinical and clinical
development for treatment of hepatitis C infection (68). Intrigu-
ingly, as summarized in Fig. 10, except for F164L, which confers
DENV resistance to SDM25N and AM404 and localizes at the
cytosolic loop between TMD3 and TMD4 (65, 67), all other drug
resistancemutations aremapped in the transmembrane domains.
Furthermore, except for DENV V63 and YFV P219 mutations,
which specifically confer resistance to spiropyrazolopyridone
compound-14a and BDAA, respectively, all other DENV and YFV
drug resistance mutations identified thus far confer resistance to
multiple drugs (25). Particularly, while each of the DENV P104,
A119, and F164 mutations confers resistance to AM404 and/or
FIG 8 Sensitivity of YFV to BDAA in C6/C36 cells. C6/C36 cells were infected
with YFV 17D or mutant virus at an MOI of 0.1 and mock treated or treated
with indicated concentrations of BDAA for 48 h. Total cellular RNAs were
extracted to detect YFV RNA in a qRT-PCR assay, using Aedes albopictus S7
ribosomal mRNA as the internal control. Values are percentages relative to
mock-treated controls. Data presented are means from four independent rep-
licates ( standard deviation).
FIG 7 Antiviral activity of BDAA against recombinant YFV with a P219G mutation in Huh7.5 cells. (A to C) Replication kinetics of P219G recombinant YFV.
Huh7.5 cells were infected with cell-associated viruses harvested from YFV 17D or P219G RNA-transfected Huh7.5 cells at an MOI of 0.1 for 1 h. Intracellular
viral RNA (A) and yields of cell-associated virions (B) and secreted infectious virions (C) at the indicated times postinfectionwere quantified in a qRT-PCR assay
and plaque assay, respectively. YFV RNAwas normalized as described for Fig. 6A. (D and E) Sensitivity of YFV P219G to BDAA. Huh7.5 cells were infected with
cell-associated YFV 17D or P219GYFV at anMOI of 0.1 andmock treated or treated with the indicated concentrations of BDAA for 48 h. Total cellular RNAwas
extracted to detect YFV RNA by qRT-PCR using -actin as an internal control. Values are percentages relative to mock-treated controls (D). Supernatants from
the cultures were harvested to determine the virus yields in a plaque assay in Vero cells (E). Data presented are means from four independent replicate
experiments ( standard deviation).
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SDM25N (65, 67), the DENVT108mutation confers resistance to
AZD0530 and dasatinib, which disruptDENVRNA replication by
inhibition of cellular Fyn kinase (64). Accordingly, we speculate
that while spiropyrazolopyridone and BDAA, the only two NS4B
inhibitors with a very narrow antiviral spectrum and demon-
strated in vivo antiviral efficacy, may directly target NS4B protein;
other NS4B inhibitors may disrupt NS4B function via targeting
host cellular enzymes or other proteins that interact with NS4B or
regulate NS4B function. The fact that the majority of drug resis-
tancemutationsmapwithin the transmembrane domain of NS4B
strongly suggests that interruption of the “intramembrane” inter-
action of NS4B with other viral and host membrane proteins
might be the most important targets of the small molecular anti-
viral compounds. However, because the DENV TMD5, spanning
themembrane from the ER lumen to the cytoplasm,may flip back
to the ER lumen upon cleavage at its C terminus by NS2B/NS3
protease during polyprotein processing (53), it is also possible that
BDAA interacts with YFV NS4B to alter its membrane topology.
In fact, proline is frequently observed as the first residue of a trans-
membrane  helix due to its conformational rigidity, whereas re-
placement with a glycine tends to disrupt the helical structure due
to its high flexibility. Hence, the observed reduction of replication
fitness of P219G YFV could be due to an alteredmembrane topol-
ogy of pTMD5. Moreover, the strict requirement of P219 for the
susceptibility of YFV to BDAA strongly suggests that YFV NS4B
structural features conferred by this specific amino acid residue
may favor BDAA binding. This hypothesis will be investigated in
our future studies.
Traditionally, virus-encoded enzymes are primary antiviral
targets (17, 69). However, nonenzymatic viral structural and non-
structural proteins have been shown to be the targets of highly
selective and potent antiviral agents over the last decade, as high-
lighted by FDA-approved HCV NS5A inhibitor as well as HCV
NS4B inhibitors, and alsoHIV andHBV capsid inhibitors that are
currently under development (70–72). Among the flaviviral NS4B
inhibitors, only spiropyrazolopyridone compound 14a was re-
cently reported to significantly reduce the viremia of DENV-2 in
an AG129 mice model when mice were treated with the inhibitor
FIG9 In vivo efficacy of BDAA in a hamstermodel of lethal YFV infection. Female Syrian golden hamsters were challengedwith Jimenez, a hamster-adapted YFV
strain, via i.p. injection (10 CC50/animal). Three groups of infected animals were treated with escalated doses of BDAA twice daily (BID) via oral administration
for 7 days, beginning 4 h prior to infection. Animals treated with ribavirin served as positive controls, and a placebo-treated group served as a negative control.
Each infected group had 10 animals. Sham-infected controls were either treated with the highest dose of BDAA to monitor toxicity or placebo treated (n 5).
A group of 5 animals without any treatment served as normal controls. (A) The effect of treatment on mortality of hamsters infected with YFV. *, P 
 0.05
compared with placebo. (B)Weight change between 3 and 6 dpi from hamsters infected with YFV and treated with various doses of BDAA or with ribavirin. ***,
P
 0.001; **, P
 0.01; *, P
 0.05 (compared with placebo). (C) The effect of BDAA at various doses or ribavirin on serumALT at 6 dpi from hamsters infected
with YFV. ***, P
 0.001; **, P
 0.01. (D) Virus titers in serum on day 4 of YFV-infected hamsters treated with various doses of BDAA or with ribavirin. ***,
P
 0.001; **, P
 0.01; *, P
 0.05.
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immediately after infection or when treatment was delayed for 48
h (63). Herein, we showed, for the first time, that an YFV NS4B
inhibitor, BDAA, protected 90% of YFV-infected hamsters from
death, significantly reduced viral load by greater than 2 logs, and
attenuated virus infection-induced liver injury and body weight
loss. We have thus proved the concept that NS4B is a viable anti-
viral target against YFV and we have reached a critical milestone
toward the development of specific antiviral therapeutics for clin-
icalmanagement of yellow fever. In addition, potent and safe anti-
YFV agents may also be used as prophylaxis means for nonimmu-
nized residents and travelers during outbreaks in regions where
YFV is endemic.
ACKNOWLEDGMENTS
We acknowledge support from the Nonclinical and Preclinical Services
Program of NIAID, National Institutes of Health, Department of Health
and Human Services, under contracts HHSN2722011000221 (scale-up
synthesis), HHSN272201100019I (in vitro antiviral spectrum screening),
and HHSN272201000039I (efficacy study with hamsters).
FUNDING INFORMATION
This work was supported by theNational Institutes of Health (AI104636),
a sponsored research program fromUnither Virology, LLC, and the Hep-
atitis B Foundation (through an appropriation from the Commonwealth
of Pennsylvania). The founders had no role in study design, data collec-
tion and analysis, decision to publish, or preparation of the manuscript.
REFERENCES
1. Monath TP, Vasconcelos PF. 2015. Yellow fever. J Clin Virol 64:160–173.
http://dx.doi.org/10.1016/j.jcv.2014.08.030.
2. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. 1981.
Persistence of neutralizing antibody 30-35 years after immunization with
17D yellow fever vaccine. Bull World Health Organ 59:895–900.
3. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L’Age-Stehr J. 1998.
Development of viremia and humoral and cellular parameters of immune
activation after vaccination with yellow fever virus strain 17D: a model of
human flavivirus infection. J Med Virol 56:159–167. http://dx.doi.org/10
.1002/(SICI)1096-9071(199810)56:2
159::AID-JMV103.0.CO;2-B.
4. Jentes ES, Poumerol G, Gershman MD, Hill DR, Lemarchand J, Lewis
RF, Staples JE, Tomori O, Wilder-Smith A, Monath TP, Informal
WHO Working Group on Geographic Risk for Yellow Fever. 2011. The
revised global yellow fever risk map and recommendations for vaccina-
tion, 2010: consensus of the Informal WHO Working Group on Geo-
graphic Risk for Yellow Fever. Lancet Infect Dis 11:622–632. http://dx.doi
.org/10.1016/S1473-3099(11)70147-5.
5. Maciel M, Jr, Cruz Fda S, Cordeiro MT, da Motta MA, Cassemiro KM,
Maia Rde C, de Figueiredo RC, Galler R, Freire Mda S, August JT,
Marques ET, Dhalia R. 2015. A DNA vaccine against yellow fever virus:
development and evaluation. PLoS Negl Trop Dis 9:e0003693. http://dx
.doi.org/10.1371/journal.pntd.0003693.
6. Muyanja E, Ssemaganda A, Ngauv P, Cubas R, Perrin H, Srinivasan D,
Canderan G, Lawson B, Kopycinski J, Graham AS, Rowe DK, Smith MJ,
Isern S, Michael S, Silvestri G, Vanderford TH, Castro E, Pantaleo G,
Singer J, Gillmour J, Kiwanuka N, Nanvubya A, Schmidt C, Birungi J,
Cox J, Haddad EK, Kaleebu P, Fast P, Sekaly RP, Trautmann L,
Gaucher D. 2014. Immune activation alters cellular and humoral re-
sponses to yellow fever 17D vaccine. J Clin Invest 124:3147–3158. http:
//dx.doi.org/10.1172/JCI75429.
7. Akondy RS, Johnson PL, Nakaya HI, Edupuganti S, Mulligan MJ,
Lawson B, Miller JD, Pulendran B, Antia R, Ahmed R. 2015. Initial viral
load determines the magnitude of the human CD8 T cell response to
yellow fever vaccination. Proc Natl Acad Sci U S A 112:3050–3055. http:
//dx.doi.org/10.1073/pnas.1500475112.
8. Julander JG. 2013. Experimental therapies for yellow fever. Antiviral Res
97:169–179. http://dx.doi.org/10.1016/j.antiviral.2012.12.002.
9. Beasley DW, McAuley AJ, Bente DA. 2015. Yellow fever virus: genetic
and phenotypic diversity and implications for detection, prevention and
therapy. Antiviral Res 115:48–70. http://dx.doi.org/10.1016/j.antiviral
.2014.12.010.
10. Harris E, Holden KL, Edgil D, Polacek C, Clyde K. 2006. Molecular
biology of flaviviruses. Novartis Found Symp 277:23–39. http://dx.doi.org
/10.1002/0470058005.ch3.
11. Selisko B, Wang C, Harris E, Canard B. 2014. Regulation of flavivirus
RNA synthesis and replication. Curr Opin Virol 9:74–83. http://dx.doi
.org/10.1016/j.coviro.2014.09.011.
12. Diamond MS, Pierson TC. 2015. Molecular insight into dengue virus
pathogenesis and its implications for disease control. Cell 162:488–492.
http://dx.doi.org/10.1016/j.cell.2015.07.005.
13. Laurent-Rolle M, Morrison J, Rajsbaum R, Macleod JM, Pisanelli G,
Pham A, Ayllon J, Miorin L, Martinez-Romero C, ten Oever BR,
Garcia-Sastre A. 2014. The interferon signaling antagonist function of
yellow fever virus NS5 protein is activated by type I interferon. Cell Host
Microbe 16:314–327. http://dx.doi.org/10.1016/j.chom.2014.07.015.
14. Munoz-Jordan JL, Laurent-Rolle M, Ashour J, Martinez-Sobrido L,
Ashok M, Lipkin WI, Garcia-Sastre A. 2005. Inhibition of alpha/beta
interferon signaling by the NS4B protein of flaviviruses. J Virol 79:8004–
8013. http://dx.doi.org/10.1128/JVI.79.13.8004-8013.2005.
FIG 10 Flavivirus NS4B membrane topology and locations of drug-resistant amino acid substitutions.
Guo et al.











15. Lim SP, Wang QY, Noble CG, Chen YL, Dong H, Zou B, Yokokawa F,
Nilar S, Smith P, Beer D, Lescar J, Shi PY. 2013. Ten years of dengue
drug discovery: progress and prospects. Antiviral Res 100:500–519. http:
//dx.doi.org/10.1016/j.antiviral.2013.09.013.
16. Behnam MA, Nitsche C, Boldescu V, Klein CD. 2016. The medicinal
chemistry of dengue virus. J Med Chem 59:5622–5649. http://dx.doi.org
/10.1021/acs.jmedchem.5b01653.
17. Chang J, Block TM, Guo JT. 2013. Antiviral therapies targeting host ER
alpha-glucosidases: current status and future directions. Antiviral Res 99:
251–260. http://dx.doi.org/10.1016/j.antiviral.2013.06.011.
18. Noble CG, Chen YL, Dong H, Gu F, Lim SP, Schul W, Wang QY, Shi
PY. 2010. Strategies for development of dengue virus inhibitors. Antiviral
Res 85:450–462. http://dx.doi.org/10.1016/j.antiviral.2009.12.011.
19. Noble CG, Shi PY. 2012. Structural biology of dengue virus enzymes:
towards rational design of therapeutics. Antiviral Res 96:115–126. http:
//dx.doi.org/10.1016/j.antiviral.2012.09.007.
20. Scaturro P, Trist IM, Paul D, Kumar A, Acosta EG, Byrd CM, Jordan
R, Brancale A, Bartenschlager R. 2014. Characterization of the mode of
action of a potent dengue virus capsid inhibitor. J Virol 88:11540–11555.
http://dx.doi.org/10.1128/JVI.01745-14.
21. Wu H, Bock S, Snitko M, Berger T, Weidner T, Holloway S, Kanitz
M, Diederich WE, Steuber H, Walter C, Hofmann D, Weissbrich B,
Spannaus R, Acosta EG, Bartenschlager R, Engels B, Schirmeister T,
Bodem J. 2015. Novel dengue virus NS2B/NS3 protease inhibitors.
Antimicrob Agents Chemother 59:1100–1109. http://dx.doi.org/10
.1128/AAC.03543-14.
22. Timiri AK, Sinha BN, Jayaprakash V. 2016. Progress and prospects on
DENV protease inhibitors. Eur J Med Chem 117:125–143. http://dx.doi
.org/10.1016/j.ejmech.2016.04.008.
23. Behnam MA, Graf D, Bartenschlager R, Zlotos DP, Klein CD. 2015.
Discovery of nanomolar dengue and West Nile virus protease inhibitors
containing a 4-benzyloxyphenylglycine residue. J Med Chem 58:9354–
9370. http://dx.doi.org/10.1021/acs.jmedchem.5b01441.
24. Byrd CM, Grosenbach DW, Berhanu A, Dai D, Jones KF, Cardwell KB,
Schneider C, Yang G, Tyavanagimatt S, Harver C, Wineinger KA, Page
J, Stavale E, Stone MA, Fuller KP, Lovejoy C, Leeds JM, Hruby DE,
Jordan R. 2013. Novel benzoxazole inhibitor of dengue virus replication
that targets the NS3 helicase. Antimicrob Agents Chemother 57:1902–
1912. http://dx.doi.org/10.1128/AAC.02251-12.
25. Xie X, Zou J, Wang QY, Shi PY. 2015. Targeting dengue virus NS4B
protein for drug discovery. Antiviral Res 118:39–45. http://dx.doi.org/10
.1016/j.antiviral.2015.03.007.
26. Zou B, Chan WL, Ding M, Leong SY, Nilar S, Seah PG, Liu W, Karuna
R, Blasco F, Yip A, Chao A, Susila A, Dong H, Wang QY, Xu HY, Chan
K, Wan KF, Gu F, Diagana TT, Wagner T, Dix I, Shi PY, Smith PW.
2015. Lead optimization of spiropyrazolopyridones: a new and potent
class of dengue virus inhibitors. ACSMedChemLett 6:344–348. http://dx
.doi.org/10.1021/ml500521r.
27. Lim SP, Sonntag LS, Noble C, Nilar SH, Ng RH, Zou G, Monaghan P,
Chung KY, Dong H, Liu B, Bodenreider C, Lee G, Ding M, Chan WL,
Wang G, Jian YL, Chao AT, Lescar J, Yin Z, Vedananda TR, Keller TH,
Shi PY. 2011. Smallmolecule inhibitors that selectively block dengue virus
methyltransferase. J Biol Chem 286:6233–6240. http://dx.doi.org/10.1074
/jbc.M110.179184.
28. Lim SP, Noble CG, Shi PY. 2015. The dengue virus NS5 protein as a target
for drug discovery. Antiviral Res 119:57–67. http://dx.doi.org/10.1016/j
.antiviral.2015.04.010.
29. Chen YL, Yokokawa F, Shi PY. 2015. The search for nucleoside/
nucleotide analog inhibitors of dengue virus. Antiviral Res 122:12–19.
http://dx.doi.org/10.1016/j.antiviral.2015.07.010.
30. Byrd CM, Dai D, Grosenbach DW, Berhanu A, Jones KF, Cardwell KB,
Schneider C, Wineinger KA, Page JM, Harver C, Stavale E, Tyavanagi-
matt S, Stone MA, Bartenschlager R, Scaturro P, Hruby DE, Jordan R.
2013. A novel inhibitor of dengue virus replication that targets the capsid
protein. Antimicrob Agents Chemother 57:15–25. http://dx.doi.org/10
.1128/AAC.01429-12.
31. Zou J, Xie X, Wang QY, Dong H, Lee MY, Kang C, Yuan Z, Shi PY.
2015. Characterization of dengue virus NS4A and NS4B protein interac-
tion. J Virol 89:3455–3470. http://dx.doi.org/10.1128/JVI.03453-14.
32. Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, Kondreddi
RR, Niyomrattanakit P, Lakshminarayana SB, Goh A, Xu HY, Liu W,
Liu B, Lim JY, Ng CY, Qing M, Lim CC, Yip A, Wang G, Chan WL, Tan
HP, Lin K, Zhang B, Zou G, Bernard KA, Garrett C, Beltz K, Dong M,
Weaver M, He H, Pichota A, Dartois V, Keller TH, Shi PY. 2009. An
adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A
106:20435–20439. http://dx.doi.org/10.1073/pnas.0907010106.
33. Nguyen NM, Tran CN, Phung LK, Duong KT, Huynh Hle A, Farrar J,
Nguyen QT, Tran HT, Nguyen CV, Merson L, Hoang LT, Hibberd ML,
Aw PP, Wilm A, Nagarajan N, Nguyen DT, Pham MP, Nguyen TT,
Javanbakht H, Klumpp K, Hammond J, Petric R, Wolbers M, Nguyen
CT, Simmons CP. 2013. A randomized, double-blind placebo controlled
trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J
Infect Dis 207:1442–1450. http://dx.doi.org/10.1093/infdis/jis470.
34. Chen YL, Abdul Ghafar N, Karuna R, Fu Y, Lim SP, Schul W, Gu F,
Herve M, Yokohama F, Wang G, Cerny D, Fink K, Blasco F, Shi PY.
2014. Activation of peripheral blood mononuclear cells by dengue virus
infection depotentiates balapiravir. J Virol 88:1740–1747. http://dx.doi
.org/10.1128/JVI.02841-13.
35. Julander JG, Bantia S, Taubenheim BR, Minning DM, Kotian P, Mor-
rey JD, Smee DF, Sheridan WP, Babu YS. 2014. BCX4430, a novel
nucleoside analog, effectively treats yellow fever in a hamster model. An-
timicrob Agents Chemother 58:6607–6614. http://dx.doi.org/10.1128
/AAC.03368-14.
36. Julander JG, Furuta Y, Shafer K, Sidwell RW. 2007. Activity of T-1106 in
a hamster model of yellow fever virus infection. Antimicrob Agents Che-
mother 51:1962–1966. http://dx.doi.org/10.1128/AAC.01494-06.
37. Julander JG, Shafer K, Smee DF, Morrey JD, Furuta Y. 2009. Activity of
T-705 in a hamster model of yellow fever virus infection in comparison
with that of a chemically related compound, T-1106. Antimicrob Agents
Chemother 53:202–209. http://dx.doi.org/10.1128/AAC.01074-08.
38. Julander JG, Jha AK, Choi JA, Jung KH, Smee DF, Morrey JD, Chu CK.
2010. Efficacy of 2=-C-methylcytidine against yellow fever virus in cell
culture and in a hamster model. Antiviral Res 86:261–267. http://dx.doi
.org/10.1016/j.antiviral.2010.03.004.
39. Julander JG, Morrey JD, Blatt LM, Shafer K, Sidwell RW. 2007. Com-
parison of the inhibitory effects of interferon alfacon-1 and ribavirin on
yellow fever virus infection in a hamstermodel. Antiviral Res 73:140–146.
http://dx.doi.org/10.1016/j.antiviral.2006.08.008.
40. Patkar CG, Larsen M, Owston M, Smith JL, Kuhn RJ. 2009. Identifica-
tion of inhibitors of yellow fever virus replication using a replicon-based
high-throughput assay. Antimicrob Agents Chemother 53:4103–4114.
http://dx.doi.org/10.1128/AAC.00074-09.
41. Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines for
subgenomic and genomic hepatitis C virus RNA replication. J Virol 76:
13001–13014. http://dx.doi.org/10.1128/JVI.76.24.13001-13014.2002.
42. Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, Strauss JH. 1985.
Nucleotide sequence of yellow fever virus: implications for flavivirus gene
expression and evolution. Science 229:726–733. http://dx.doi.org/10
.1126/science.4023707.
43. Bredenbeek PJ, Kooi EA, Lindenbach B, Huijkman N, Rice CM, Spaan
WJ. 2003. A stable full-length yellow fever virus cDNA clone and the role
of conserved RNA elements in flavivirus replication. J Gen Virol 84:1261–
1268. http://dx.doi.org/10.1099/vir.0.18860-0.
44. Qu X, Pan X, Weidner J, Yu W, Alonzi D, Xu X, Butters T, Block T,
Guo JT, Chang J. 2011. Inhibitors of endoplasmic reticulum -glucosi-
dases potently suppress hepatitis C virus virion assembly and release. An-
timicrob Agents Chemother 55:1036–1044. http://dx.doi.org/10.1128
/AAC.01319-10.
45. Guo F, Zhao X, Gill T, Zhou Y, Campagna M, Wang L, Liu F, Zhang
P, DiPaolo L, Du Y, Xu X, Jiang D, Wei L, Cuconati A, Block TM, Guo
JT, Chang J. 2014. An interferon-beta promoter reporter assay for high
throughput identification of compounds against multiple RNA viruses.
Antiviral Res 107:56–65. http://dx.doi.org/10.1016/j.antiviral.2014.04
.010.
46. Jiang D, Weidner JM, Qing M, Pan XB, Guo H, Xu C, Zhang X, Birk
A, Chang J, Shi PY, Block TM, Guo JT. 2010. Identification of five
interferon-induced cellular proteins that inhibit West Nile virus and den-
gue virus infections. J Virol 84:8332–8341. http://dx.doi.org/10.1128/JVI
.02199-09.
47. Chang J, Warren TK, Zhao X, Gill T, Guo F, Wang L, Comunale MA,
Du Y, Alonzi DS, Yu W, Ye H, Liu F, Guo JT, Mehta A, Cuconati A,
Butters TD, Bavari S, Xu X, Block TM. 2013. Small molecule inhibitors
of ER alpha-glucosidases are active against multiple hemorrhagic fever
viruses. Antiviral Res 98:432–440. http://dx.doi.org/10.1016/j.antiviral
.2013.03.023.
48. Le Fur G, Vaucher N, Perrier ML, Flamier A, Benavides J, Renault C,
Benzodiazepine Inhibitors Targeting YFV NS4B











Dubroeucq MC, Gueremy C, Uzan A. 1983. Differentiation between two
ligands for peripheral benzodiazepine binding sites, [3H]RO5-4864 and
[3H]PK 11195, by thermodynamic studies. Life Sci 33:449–457. http://dx
.doi.org/10.1016/0024-3205(83)90794-4.
49. Speth RC, Wastek GJ, Yamamura HI. 1979. Benzodiazepine receptors:
temperature dependence of [3H]flunitrazepam binding. Life Sci 24:351–
357. http://dx.doi.org/10.1016/0024-3205(79)90331-X.
50. Taliani S, Da Settimo F, Da Pozzo E, Chelli B, Martini C. 2009.
Translocator protein ligands as promising therapeutic tools for anxiety
disorders. Curr Med Chem 16:3359–3380. http://dx.doi.org/10.2174
/092986709789057653.
51. Sieghart W, Ramerstorfer J, Sarto-Jackson I, Varagic Z, Ernst M. 2012.
A novel GABA(A) receptor pharmacology: drugs interacting with the al-
pha() beta(-) interface. Br J Pharmacol 166:476–485. http://dx.doi.org
/10.1111/j.1476-5381.2011.01779.x.
52. Zisterer DM, Williams DC. 1997. Peripheral-type benzodiazepine
receptors. Gen Pharmacol 29:305–314. http://dx.doi.org/10.1016
/S0306-3623(96)00473-9.
53. Miller S, Sparacio S, Bartenschlager R. 2006. Subcellular localization and
membrane topology of the dengue virus type 2 non-structural protein 4B.
J Biol Chem 281:8854–8863. http://dx.doi.org/10.1074/jbc.M512697200.
54. Welsch S, Miller S, Romero-Brey I, Merz A, Bleck CK, Walther P, Fuller
SD, Antony C, Krijnse-Locker J, Bartenschlager R. 2009. Composition
and three-dimensional architecture of the dengue virus replication and
assembly sites. Cell Host Microbe 5:365–375. http://dx.doi.org/10.1016/j
.chom.2009.03.007.
55. Green AM, Beatty PR, Hadjilaou A, Harris E. 2014. Innate immunity to
dengue virus infection and subversion of antiviral responses. J Mol Biol
426:1148–1160. http://dx.doi.org/10.1016/j.jmb.2013.11.023.
56. Henderson EA, Alber DG, Baxter RC, Bithell SK, Budworth J, Carter
MC, Chubb A, Cockerill GS, Dowdell VC, Fraser IJ, Harris RA, Keegan
SJ, Kelsey RD, Lumley JA, Stables JN, Weerasekera N, Wilson LJ,
Powell KL. 2007. 1,4-Benzodiazepines as inhibitors of respiratory syncy-
tial virus. The identification of a clinical candidate. J Med Chem 50:1685–
1692.
57. Zhang P, Zhang N, Korba BE, Hosmane RS. 2005. Synthesis and in vitro
anti-hepatitis B and C virus activities of ring-expanded (‘fat’) nucleobase
analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring
system. Bioorg Med Chem Lett 15:5397–5401. http://dx.doi.org/10.1016
/j.bmcl.2005.09.015.
58. Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, Peet
NP, Majgier-Baranowska H, Williams JD, Patel I, Moir DT, Bavari S,
Ray R, Farzan MR, Rong L, Bowlin TL. 2011. Identification of a small-
molecule entry inhibitor for filoviruses. J Virol 85:3106–3119. http://dx
.doi.org/10.1128/JVI.01456-10.
59. Schimer J, Cigler P, Vesely J, Grantz Saskova K, Lepsik M, Brynda J,
Rezacova P, Kozisek M, Cisarova I, Oberwinkler H, Kraeusslich HG,
Konvalinka J. 2012. Structure-aided design of novel inhibitors of HIV
protease based on a benzodiazepine scaffold. J Med Chem 55:10130–
10135. http://dx.doi.org/10.1021/jm301249q.
60. Zmurko J, Neyts J, Dallmeier K. 2015. Flaviviral NS4b, chameleon and
jack-in-the-box roles in viral replication and pathogenesis, and a molec-
ular target for antiviral intervention. RevMed Virol 25:205–223. http://dx
.doi.org/10.1002/rmv.1835.
61. Zou J, Xie X, Lee le T, Chandrasekaran R, Reynaud A, Yap L, Wang QY,
Dong H, Kang C, Yuan Z, Lescar J, Shi PY. 2014. Dimerization of
flavivirus NS4B protein. J Virol 88:3379–3391. http://dx.doi.org/10.1128
/JVI.02782-13.
62. Bartenschlager R, Miller S. 2008. Molecular aspects of dengue virus
replication. Future Microbiol 3:155–165. http://dx.doi.org/10.2217
/17460913.3.2.155.
63. Wang QY, Dong H, Zou B, Karuna R, Wan KF, Zou J, Susila A, Yip A,
Shan C, Yeo KL, Xu H, Ding M, Chan WL, Gu F, Seah PG, Liu W,
Lakshminarayana SB, Kang C, Lescar J, Blasco F, Smith PW, Shi PY.
2015. Discovery of dengue virus NS4B inhibitors. J Virol 89:8233–8244.
http://dx.doi.org/10.1128/JVI.00855-15.
64. de Wispelaere M, LaCroix AJ, Yang PL. 2013. The small molecules
AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn
kinase. J Virol 87:7367–7381. http://dx.doi.org/10.1128/JVI.00632-13.
65. van Cleef KW, Overheul GJ, Thomassen MC, Kaptein SJ, Davidson AD,
Jacobs M, Neyts J, van Kuppeveld FJ, van Rij RP. 2013. Identification of
a new dengue virus inhibitor that targets the viral NS4B protein and re-
stricts genomic RNA replication. Antiviral Res 99:165–171. http://dx.doi
.org/10.1016/j.antiviral.2013.05.011.
66. Xie X, Wang QY, Xu HY, Qing M, Kramer L, Yuan Z, Shi PY. 2011.
Inhibition of dengue virus by targeting viral NS4B protein. J Virol 85:
11183–11195. http://dx.doi.org/10.1128/JVI.05468-11.
67. van Cleef KW, Overheul GJ, Thomassen MC, Marjakangas JM, van
Rij RP. 2016. Escape mutations in NS4B render dengue virus insensi-
tive to the antiviral activity of the paracetamol metabolite AM404.
Antimicrob Agents Chemother 60:2554–2557. http://dx.doi.org/10
.1128/AAC.02462-15.
68. Cannalire R, Barreca ML, Manfroni G, Cecchetti V. 2016. A journey
around the medicinal chemistry of hepatitis C virus inhibitors targeting
NS4B: from target to preclinical drug candidates. J Med Chem 59:16–41.
http://dx.doi.org/10.1021/acs.jmedchem.5b00825.
69. Chang J, Block TM, Guo JT. 2015. Viral resistance of MOGS-CDG
patients implies a broad-spectrum strategy against acute virus infections.
Antivir Ther 20:257–259. http://dx.doi.org/10.3851/IMP2907.
70. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA,
Serrano-Wu MH, Langley DR, Sun JH, O’Boyle DR, II, Lemm JA,
Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA,
Hamann LG. 2010. Chemical genetics strategy identifies an HCV NS5A
inhibitor with a potent clinical effect. Nature 465:96–100. http://dx.doi
.org/10.1038/nature08960.
71. Campagna MR, Liu F, Mao R, Mills C, Cai D, Guo F, Zhao X, Ye H,
Cuconati A, Guo H, Chang J, Xu X, Block TM, Guo JT. 2013.
Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B
virus nucleocapsids. J Virol 87:6931–6942. http://dx.doi.org/10.1128
/JVI.00582-13.
72. Zlotnick A, Venkatakrishnan B, Tan Z, Lewellyn E, Turner W, Francis
S. 2015. Core protein: a pleiotropic keystone in the HBV life cycle. Anti-
viral Res 121:82–93. http://dx.doi.org/10.1016/j.antiviral.2015.06.020.
Guo et al.





ber 16, 2016 by UTAH STATE UNIV
http://jvi.asm.org/
D
ow
nloaded from
 
